Drug intelligence / Profile preview

carbocisteine

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral
01

Overview

Carbocisteine is a mucolytic agent used to reduce the viscosity of sputum, making it easier to cough up and clear from the respiratory tract. It is primarily indicated for chronic obstructive pulmonary disease (COPD), bronchiectasis, and other respiratory conditions characterized by excessive or thick mucus production. Carbocisteine works by modifying the structure of mucus glycoproteins, thereby decreasing their thickness and stickiness. Additionally, it may have antioxidant properties through activation of protein kinase B (Akt) phosphorylation and can suppress inflammatory pathways such as NF-κB and ERK1/2 MAPK signaling. This drug was first described in 1951 and introduced into medical use in 1960[2][6][7]. It is available as oral capsules or syrup under prescription.

Brand names
Mucodyne
Other names
carbocysteineL-carbocisteine
02

Targets

MUC2 (Mucin-2)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)KEAP1 (Kelch-like ECH-associated protein 1)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on carbocisteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carbocisteine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call